Breadcrumb

Kazusa Ishii, M.D., M.P.H.

Kazusa Ishii, M.D., M.P.H.

  • Center for Cancer Research
  • National Cancer Institute
Physician-Scientist Early Investigator
Center for Immuno-Oncology
Head, Hematologic Malignancies Cellular Therapy Group

RESEARCH SUMMARY

Dr. Kazusa Ishii researches cell therapy for various hematologic malignancies and non-malignant diseases. Her research focuses on 1) identification of therapeutically targetable antigens, 2) discovery, pre-clinical development and clinical translation of novel cell therapies, and 3) improving our mechanistic understanding of how T-cell-mediated therapies and the host’s immune environment affect clinical responses and disease phenotypes.

Areas of Expertise

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Recent Publications

Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors

Ishii K*, Davies JS, Sinkoe AL, Nguyen KA, Norberg SM, McIntosh CP, Kadakia T, Serna C, Rae Z, Kelly MC, Hinrichs CS*. *co-corresponding
Science Advances. 9(30): eadg9845, 2023.
Full-Text Article
[ Journal Article ]

Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients

Ishii K*, Pouzolles M, Chien CD, Erwin-Cohen RA, Kohler ME, Qin H, Lei H, Kuhn S, Ombrello AK, Dulau-Florea A, Eckhaus MA, Shalabi H, Yates B, Lichtenstein DA, Zimmermann VS, Kondo T, Shern JF, Young HA, Taylor N, Shah NN*, Fry TJ*. *co-corresponding
J Clin Invest. 130(10): 5425-5443, 2020. [ Journal Article ]

Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor

Qin H, Ishii K, Nguyen S, Su PP, Burk CR, Kim BH, Duncan BB, Tarun S, Shah NN, Kohler ME, Fry TJ.
Blood. 132(18): 1899-1910, 2018. [ Journal Article ]

Applying a clinical lens to animal models of CAR-T cell therapies

Duncan BB, Dunbar CE, Ishii K*. *corresponding
Mol Ther Methods Clin Dev. 27: 17-31, 2022. [ Journal Article ]

CD22 TCR-engineered T cells exert anti-leukemia cytotoxicity without causing inflammatory responses

Ishii K, Liu Z, Davies JS, Nguyen KA, McIntosh, CP, Kadakia T, Norberg SM, Rae Z, Achar S, Altan-Bonnet G, Wu X, Kelly MC, Taylor N, Hinrichs CS
Blood. 142 (Supplement 1): 2085, 2023.
Full-Text Article

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.

Team

Postbaccalaureate Fellow
Kilyna Nguyen

News

Learn more about CCR research advances, new discoveries and more
on our news section.